472 related articles for article (PubMed ID: 19540513)
1. A new cystic fibrosis newborn screening algorithm: IRT/IRT1 upward arrow/DNA.
Sontag MK; Wright D; Beebe J; Accurso FJ; Sagel SD
J Pediatr; 2009 Nov; 155(5):618-22. PubMed ID: 19540513
[TBL] [Abstract][Full Text] [Related]
2. Two-tiered immunoreactive trypsinogen-based newborn screening for cystic fibrosis in Colorado: screening efficacy and diagnostic outcomes.
Sontag MK; Hammond KB; Zielenski J; Wagener JS; Accurso FJ
J Pediatr; 2005 Sep; 147(3 Suppl):S83-8. PubMed ID: 16202790
[TBL] [Abstract][Full Text] [Related]
3. A survey of newborn screening for cystic fibrosis in Europe.
Southern KW; Munck A; Pollitt R; Travert G; Zanolla L; Dankert-Roelse J; Castellani C;
J Cyst Fibros; 2007 Jan; 6(1):57-65. PubMed ID: 16870510
[TBL] [Abstract][Full Text] [Related]
4. Combining immunoreactive trypsinogen and pancreatitis-associated protein assays, a method of newborn screening for cystic fibrosis that avoids DNA analysis.
Sarles J; Berthézène P; Le Louarn C; Somma C; Perini JM; Catheline M; Mirallié S; Luzet K; Roussey M; Farriaux JP; Berthelot J; Dagorn JC
J Pediatr; 2005 Sep; 147(3):302-5. PubMed ID: 16182665
[TBL] [Abstract][Full Text] [Related]
5. Newborn screening for cystic fibrosis in Wisconsin: nine-year experience with routine trypsinogen/DNA testing.
Rock MJ; Hoffman G; Laessig RH; Kopish GJ; Litsheim TJ; Farrell PM
J Pediatr; 2005 Sep; 147(3 Suppl):S73-7. PubMed ID: 16202788
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic dilemmas resulting from the immunoreactive trypsinogen/DNA cystic fibrosis newborn screening algorithm.
Parad RB; Comeau AM
J Pediatr; 2005 Sep; 147(3 Suppl):S78-82. PubMed ID: 16202789
[TBL] [Abstract][Full Text] [Related]
7. Improving the Sensitivity and Positive Predictive Value in a Cystic Fibrosis Newborn Screening Program Using a Repeat Immunoreactive Trypsinogen and Genetic Analysis.
Sontag MK; Lee R; Wright D; Freedenberg D; Sagel SD
J Pediatr; 2016 Aug; 175():150-158.e1. PubMed ID: 27131402
[TBL] [Abstract][Full Text] [Related]
8. Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: a cystic fibrosis newborn screening model demonstrating increased sensitivity but more carrier detections.
Comeau AM; Parad RB; Dorkin HL; Dovey M; Gerstle R; Haver K; Lapey A; O'Sullivan BP; Waltz DA; Zwerdling RG; Eaton RB
Pediatrics; 2004 Jun; 113(6):1573-81. PubMed ID: 15173476
[TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of newborn screening for cystic fibrosis: a simulation study.
Nshimyumukiza L; Bois A; Daigneault P; Lands L; Laberge AM; Fournier D; Duplantie J; Giguère Y; Gekas J; Gagné C; Rousseau F; Reinharz D
J Cyst Fibros; 2014 May; 13(3):267-74. PubMed ID: 24238947
[TBL] [Abstract][Full Text] [Related]
10. Extended gene analysis can increase specificity of neonatal screening for cystic fibrosis.
Mérelle ME; Scheffer H; De Jong D; Dankert-Roelse JE
Acta Paediatr; 2006 Nov; 95(11):1424-8. PubMed ID: 17062471
[TBL] [Abstract][Full Text] [Related]
11. Comparison of different IRT-PAP protocols to screen newborns for cystic fibrosis in three central European populations.
Sommerburg O; Krulisova V; Hammermann J; Lindner M; Stahl M; Muckenthaler M; Kohlmueller D; Happich M; Kulozik AE; Votava F; Balascakova M; Skalicka V; Stopsack M; Gahr M; Macek M; Mall MA; Hoffmann GF
J Cyst Fibros; 2014 Jan; 13(1):15-23. PubMed ID: 23891278
[TBL] [Abstract][Full Text] [Related]
12. [Neonatal screening for cystic fibrosis].
Tellería Orriols JJ; Alonso Ramos MJ; Garrote Adrados JA; Fernández Carvajal I; Blanco Quirós A
An Esp Pediatr; 2002 Jul; 57(1):60-5. PubMed ID: 12139895
[TBL] [Abstract][Full Text] [Related]
13. Pancreatic function and extended mutation analysis in DeltaF508 heterozygous infants with an elevated immunoreactive trypsinogen but normal sweat electrolyte levels.
Massie RJ; Wilcken B; Van Asperen P; Dorney S; Gruca M; Wiley V; Gaskin K
J Pediatr; 2000 Aug; 137(2):214-20. PubMed ID: 10931414
[TBL] [Abstract][Full Text] [Related]
14. Thirty-years of screening for cystic fibrosis in East Anglia.
Calvin J; Hogg SL; McShane D; McAuley SA; Iles R; Ross-Russell R; MacLean FM; Heeley ME; Heeley AF;
Arch Dis Child; 2012 Dec; 97(12):1043-7. PubMed ID: 23076339
[TBL] [Abstract][Full Text] [Related]
15. Screening for cystic fibrosis in dried blood spots of newborns.
Audrézet MP; Costes B; Ghanem N; Fanen P; Verlingue C; Morin JF; Mercier B; Goossens M; Férec C
Mol Cell Probes; 1993 Dec; 7(6):497-502. PubMed ID: 8145780
[TBL] [Abstract][Full Text] [Related]
16. Newborn screening for cystic fibrosis is complicated by age-related decline in immunoreactive trypsinogen levels.
Rock MJ; Mischler EH; Farrell PM; Wei LJ; Bruns WT; Hassemer DJ; Laessig RH
Pediatrics; 1990 Jun; 85(6):1001-7. PubMed ID: 2187173
[TBL] [Abstract][Full Text] [Related]
17. Lessons learned from 20 years of newborn screening for cystic fibrosis.
Massie RJ; Curnow L; Glazner J; Armstrong DS; Francis I
Med J Aust; 2012 Jan; 196(1):67-70. PubMed ID: 22256939
[TBL] [Abstract][Full Text] [Related]
18. The CF-CIRC study: a French collaborative study to assess the accuracy of cystic fibrosis diagnosis in neonatal screening.
Sermet-Gaudelus I; Roussel D; Bui S; Deneuville E; Huet F; Reix P; Bellon G; Lenoir G; Edelman A
BMC Pediatr; 2006 Oct; 6():25. PubMed ID: 17018149
[TBL] [Abstract][Full Text] [Related]
19. Markedly elevated neonatal immunoreactive trypsinogen levels in the absence of cystic fibrosis gene mutations is not an indication for further testing.
Massie J; Curnow L; Tzanakos N; Francis I; Robertson CF
Arch Dis Child; 2006 Mar; 91(3):222-5. PubMed ID: 16243854
[TBL] [Abstract][Full Text] [Related]
20. Novel strategies in newborn screening for cystic fibrosis: a prospective controlled study.
Vernooij-van Langen AM; Loeber JG; Elvers B; Triepels RH; Gille JJ; Van der Ploeg CP; Reijntjens S; Dompeling E; Dankert-Roelse JE;
Thorax; 2012 Apr; 67(4):289-95. PubMed ID: 22271776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]